BiotechTube
Home/Pipeline/Enhanced Parkinson Care Innovation

Enhanced Parkinson Care Innovation

Parkinson's Disease

CommercialActive

Key Facts

Indication
Parkinson's Disease
Phase
Commercial
Status
Active
Company
Navamedic

About Navamedic

Navamedic ASA is a publicly traded, commercial-stage Nordic pharmaceutical company generating significant revenue through the marketing and distribution of approved products. Its core business model involves in-licensing, marketing, and supplying pharmaceuticals and medical nutrition, with a particular focus on areas like Parkinson's disease and inherited metabolic disorders such as PKU. The company reported 2025 revenue of MNOK 565.4 and employs approximately 45 people. Its strategy combines portfolio growth with patient support initiatives to strengthen its position in the Nordic healthcare market.

View full company profile

Therapeutic Areas

Parkinson's DiseaseInherited Metabolic Disorders (e.g., PKU)Medical Nutrition

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical
golexanoloneUmecrine CognitionPreclinical
Parkin Activator ProgramProgenraPre-clinical
Not SpecifiedAsceneuronNot Disclosed